Clinical Trial Update: A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and tolerability of Zimura (ARC1905) in combination with anti-VEGF therapy in idiopathic polypoidal choroidal vasculopathy; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Polypoidal Choroidal Vasculopathy

Drugs mentioned

• Zimura (ARC1905)

Snippet

Sponsor: Ophthotech Corporation | Conditions: Idiopathic Polypoidal Choroidal Vasculopathy | Phase 2 | Status: COMPLETED | Results posted: 2019-01-23